2-[(4-bromobenzyl)sulfonyl]ethanol | 1267213-12-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[(4-bromobenzyl)sulfonyl]ethanol
• 英文别名: 2-[(4-Bromobenzyl)sulfonyl]ethanol；2-[(4-bromophenyl)methylsulfonyl]ethanol
• CAS: 1267213-12-6
• 化学式: C₉H₁₁BrO₃S
• 分子量: 279.155
• InChiKey: CQVOAZGECAYIBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  62.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[(4-bromobenzyl)sulfonyl]ethanol 在 甲基磺酰氯 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 (R)-N-(2-((4-bromobenzyl)sulfonyl)ethyl)butan-2-amine
  参考文献：
  名称：

  [EN] IMMUNOMODULATORY COMPOUNDS
  [FR] COMPOSÉS IMMUNOMODULATEURS

  摘要：

  本发明涉及化合物及其在治疗或预防与炎症相关的疾病中的用途。

  公开号：

  WO2014023934A1
• 作为产物：
  描述：

  2-[(4-溴苄基)硫基]乙醇 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 以36%的产率得到2-[(4-bromobenzyl)sulfonyl]ethanol
  参考文献：
  名称：

  [EN] IMMUNOMODULATORY COMPOUNDS
  [FR] COMPOSÉS IMMUNOMODULATEURS

  摘要：

  本发明涉及化合物及其在治疗或预防与炎症相关的疾病中的用途。

  公开号：

  WO2014023934A1

文献信息

• [EN] IMMUNOMODULATORY COMPOUNDS<br/>[FR] COMPOSÉS IMMUNOMODULATEURS
  申请人：UNIV STRATHCLYDE

  公开号：WO2014023934A1

  公开（公告）日：2014-02-13

  This invention relates to compounds and uses thereof in the treatment or prophylaxis of diseases associated with inflammation.

  本发明涉及化合物及其在治疗或预防与炎症相关的疾病中的用途。
• Immunomodulatory Compounds
  申请人：University of Strathclyde

  公开号：US20150218116A1

  公开（公告）日：2015-08-06

  This invention relates to compounds and uses thereof in the treatment or prophylaxis of diseases associated with inflammation.

  本发明涉及化合物及其在治疗或预防与炎症相关的疾病中的用途。
• IMMUNOMODULATORY COMPOUNDS
  申请人：University of Strathclyde

  公开号：EP2882727A1

  公开（公告）日：2015-06-17
• US9598386B2
  申请人：——

  公开号：US9598386B2

  公开（公告）日：2017-03-21
• Designing Anti-inflammatory Drugs from Parasitic Worms: A Synthetic Small Molecule Analogue of the <i>Acanthocheilonema viteae</i> Product ES-62 Prevents Development of Collagen-Induced Arthritis
  作者：Lamyaa Al-Riyami、Miguel A. Pineda、Justyna Rzepecka、Judith K. Huggan、Abedawn I. Khalaf、Colin J. Suckling、Fraser J. Scott、David T. Rodgers、Margaret M. Harnett、William Harnett

  DOI：10.1021/jm401251p

  日期：2013.12.27

  In spite of increasing evidence that parasitic worms may protect humans from developing allergic and autoimmune diseases and the continuing identification of defined helminth-derived immunomodulatory molecules, to date no new anti-inflammatory drugs have been developed from these organisms. We have approached this matter in a novel manner by synthesizing a library of drug-like small molecules based upon phosphorylcholine, the active moiety of the anti-inflammatory Acanthocheilonema viteae product, ES-62, which as an immunogenic protein is unsuitable for use as a drug. Following preliminary in vitro screening for inhibitory effects responses, a sulfone-containing phosphorylcholine analogue (11a) was selected for testing in collagen-induced arthritis (CIA). Testing revealed that 11a was as effective as ES-62 in protecting DBA/1 mice from developing CIA and mirrored its mechanism of action in downregulating the TLR/IL-1R transducer, MyD88. 11a is thus a novel prototype for anti-inflammatory drug development. on relevant macrophage cytokine an in vivo model of inflammation,